Treprostinil - YUTREPIA inhalation powder | GlobalRPh Renal Dosing Master

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Review first - source-specific qualification

YUTREPIA mirror describes injection, not inhalation powder

The retrieved RX page and directory label refer to treprostinil injection. The official YUTREPIA product is inhalation powder. The RX clinical content was excluded.

Before applying: Use the inhalation-powder label and exact device; do not use injection infusion-rate instructions.

Evidence for this qualification

Selected-source comparison; independent clinician adjudication pending.

Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist

Choose a source to read (1)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

YUTREPIA: renal guidance for inhalation powder

This source only - not a merged recommendation

What matters first

Product: Adult YUTREPIA inhalation powder for labeled pulmonary hypertension indications. Capsules are inhaled with the supplied device, never swallowed or injected.

Renal action / finding: Label: no renal dose adjustment; not cleared by dialysis.
Evidence or dialysis limit: Renal PK support includes an oral study; no oral or injection dose substitution.
Monitoring / application: Inhalation powder only. Capsules must not be swallowed.

Selected-section summary, not a complete monograph. Independent clinician review remains pending. Read the exact renal measure, dates and full source below.

Product / population: Adult YUTREPIA inhalation powder for labeled pulmonary hypertension indications. Capsules are inhaled with the supplied device, never swallowed or injected.
Renal measure: Renal-impairment label conclusion; supporting ESRD study used oral treprostinil
Source revision: 06/2025
Retrieved: 2026-11-07 (not the revision date)

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Before using this finding

Renal PK support includes an oral study; no oral or injection dose substitution.

Sections 8.7, 12.3 and product administration scope

No renal dose adjustment is recommended; treprostinil is not cleared by dialysis. The renal PK discussion includes an oral treprostinil study, not direct evidence for administering an oral dose of YUTREPIA. These capsules are for inhalation through the supplied device, not swallowing. Do not substitute injection infusion rates, ORENITRAM doses or another inhaled formulation without the exact product transition instructions.

Source revision: 06/2025 | Retrieved: 2026-11-07. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8f6d534-115c-440e-bdbb-b443a29bb468

Scope: Selected named sections summarized; not a complete monograph or independent clinician approval. GlobalRPh v7.4.

Full source card / provenance

All sources, comparison tools and evidence navigation

Source-specific interpretation

What the dialysis evidence actually supports

Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.

YUTREPIA: renal guidance for inhalation powder

Source retrieved 2026-11-07 - confirm current applicability

Removal information only - not a dialysis regimen

Read the source and its limits

These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

YUTREPIA: renal guidance for inhalation powder

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Before using this finding

Renal PK support includes an oral study; no oral or injection dose substitution.

Dialysis evidence: Removal information only - not a dialysis regimen

Adult YUTREPIA inhalation powder for labeled pulmonary hypertension indications. Capsules are inhaled with the supplied device, never swallowed or injected.

Renal method: Renal-impairment label conclusion; supporting ESRD study used oral treprostinil
Retrieved: 2026-11-07

Read local renal result Open this source quick answerOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

YUTREPIA mirror describes injection, not inhalation powder

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds

Find text within this drug

Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance

Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources

Jump to renal guidance Read 1 difference / caution notes Clinician guide

Only one eligible source version is stored here. No second source is inferred from a reference link. Independent corroboration is still needed.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Source-review outline (read-only; copy and complete elsewhere)

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Population Kidney-function trend Renal replacement setting

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

Source scope / renal recommendation differences

YUTREPIA mirror describes injection, not inhalation powder

The retrieved RX page and directory label refer to treprostinil injection. The official YUTREPIA product is inhalation powder. The RX clinical content was excluded.

How to use this: Use the inhalation-powder label and exact device; do not use injection infusion-rate instructions.

YUTREPIA: renal guidance for inhalation powder Treprostinil - ORENITRAM extended-release tablets

Selected-source comparison; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Official source

YUTREPIA: renal guidance for inhalation powder

Adult YUTREPIA inhalation powder for labeled pulmonary hypertension indications. Capsules are inhaled with the supplied device, never swallowed or injected.

Method: Renal-impairment label conclusion; supporting ESRD study used oral treprostinil

Read this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scope YUTREPIA: renal guidance for inhalation powder

Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

An RX mirror and its underlying label are not independent clinical confirmations.

Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8f6d534-115c-440e-bdbb-b443a29bb468

Product identity and scope

Adult YUTREPIA inhalation powder for labeled pulmonary hypertension indications. Capsules are inhaled with the supplied device, never swallowed or injected.

RDM71-treprostinil-yutrepia-inhaled-scope · Source section: Product identity and scopeRenal section finder

Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official Compare this source

YUTREPIA: renal guidance for inhalation powder

Open original reference

Open / share this exact local source

DailyMed / product prescribing information · Adult YUTREPIA inhalation powder for labeled pulmonary hypertension indications. Capsules are inhaled with the supplied device, never swallowed or injected.

Renal method: Renal-impairment label conclusion; supporting ESRD study used oral treprostinil
Source date: 06/2025
Retrieved: 2026-11-07

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Before using this finding

Renal PK support includes an oral study; no oral or injection dose substitution.

Dialysis evidence: Removal information only - not a dialysis regimen

Selected named sections summarized; not a complete monograph or independent clinician approval.

Sections 8.7, 12.3 and product administration scope

RDM71-treprostinil-yutrepia-inhaled-label-1 · Source locator: Sections 8.7, 12.3 and product administration scope

Source identity and provenance

Source family: product_label
Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8f6d534-115c-440e-bdbb-b443a29bb468
Retrieved: 2026-11-07
Renal-function method: Renal-impairment label conclusion; supporting ESRD study used oral treprostinil
Source date/version: 06/2025
Hash meaning: Locally authored summary text; not original source HTML, XML or PDF bytes
Local summary SHA-256: 16099b4795178feb25a172dcc07998e3e6135db8296237823157d7b13bdebe9f

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 0 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8f6d534-115c-440e-bdbb-b443a29bb468
Source retrieval: 2026-11-07. This is not the source publication or label revision date.
Original source type: multisource addition
Local text SHA-256: 92836a1c2bda4732c20f3d3d273c7581e17587cf21bebdb78b59081bcd92f489
Import versus clinical validation: Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report